Group B Streptococcal Infection Clinical Trial
Official title:
Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization
The aim of this project is to identify the duration of vancomycin administration at which
group B streptococcus (GBS) colonization is eradicated from the vaginal and recto-vaginal
mucosa. This will aid in labor management and delivery planning to ensure that the mother
receives adequate GBS prophylaxis while also minimizing the duration of exposure to
vancomycin. In addition, this could prevent unnecessary prolonged hospitalization or septic
workup of neonates whose mothers received vancomycin intrapartum.
This study aims to identify the time after administration of IV vancomycin at which GBS
colonies are 100% eradicated.
Prophylaxis of group B streptococcus has been a major component of prenatal care in
preventing early onset of neonatal sepsis. While penicillin remains the gold standard
medication for prophylaxis, this medication is not an option in women who have high risk
allergic reactions to this class of medications. Furthermore, with rising rates of antibiotic
resistance to erythromycin and clindamycin, more women are requiring vancomycin for GBS
prophylaxis. While the CDC and ACOG recommend vancomycin as an alternative to penicillin for
GBS prophylaxis, little research has been conducted investigating the transplacental passage
of vancomycin.
Because of the gap in knowledge regarding intrapartum effects of IV vancomycin on GBS
colonization, neonates of women who received vancomycin are considered as inadequately
treated for GBS prophylaxis, and subsequently undergo additional observation, prolonged
hospitalization, and possible septic workup in the immediate postpartum period. Because of
this gap in knowledge, this research study investigates how quickly vaginal and recto-vaginal
GBS colonization is eradicated to aid in timing of delivery in patients with GBS colonization
who require vancomycin intrapartum.
In addition, the studies that investigated the duration of time of IV penicillin and IV
clindamycin necessary for eradication of GBS colonization only investigated vaginal
colonization, not recto-vaginal colonization. Their rationale was based on the assumption
that most cases of neonatal GBS sepsis are caused by vaginal colonization. Given that the
standard of care for GBS screening includes screening for colonization of both vaginal and
rectal mucosa, investigators also plan to compare rates of eradication of GBS in vaginal
colonies compared to recto-vaginal colonies.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05832502 -
Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without HIV (PREPARE)
|
Phase 2 | |
Completed |
NCT02142933 -
Simplified GBS Screening and Prevalence of ESBL in Pregnant Women
|
N/A | |
Completed |
NCT04596878 -
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
|
Phase 2 | |
Withdrawn |
NCT04116645 -
Time Frame for GBS Screening
|
||
Withdrawn |
NCT04227730 -
MATERNAL AND NEONATAL SCREENING FOR GROUP B STREPTOCOCCI : A Follow up STUDY
|
||
Completed |
NCT05154578 -
Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
|
Phase 2 | |
Completed |
NCT02528981 -
Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT01577108 -
Oral Probiotics Reduce Group B Streptococci Colonization in Pregnant Women
|
Phase 2 |